The field of pyschedelics is advancing rapidly with drugs such as ecstasy and magic mushrooms now becoming part of the pharmaceutical mainstream.
The sector and those companies working in it, are garnering a lots of attention from both patients and the medical industry, not least due to the fact that early studies are finding that psilocybin – the active agent in magic mushrooms – could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD).
Last year alone, there were at least 20 conferences in the United States covering the latest developments in psychedelic science and medicine.
Our Proactive virtual forum on October 7 will be a pychedelics showcase event so do join us to find out more about this exciting area.
MagicMed Industries Inc is part of the latest wave of the psychedelics revolution. Find out why
MagicMed Industries Inc has garnered quite a fan club. And it’s one that’s been willing to show the color of its money as investors recently got behind a US$1.6mln private placement.
The team is using this cash injection to “expedite and amplify” development of the MagicMed Psybrary. This is a library of new derivative molecules that are patentable
"The MagicMed Psybrary encompasses the patent portfolio and psychedelic derivative molecules that we offer as an acceleration platform to partner companies in this developing industry," said CEO Dr Joseph Tucker recently.
"Each derivative molecule in the Psybrary is a potential patented drug development candidate for our future biotech and pharmaceutical partners."
Joseph is joining us on October 7 at 1pm EST for our Virtual One2One event, which is a psychedelics showcase.
The keynote speaker is one of the leading investors in this emerging and exciting space, Henri Sant-Cassia, founding partner of The Conscious Fund, the ethical VC for plant powered medicines.
Find out how Field Trip Health is using psychedelics to promote mental wellness
Field Trip Health is the world's first mental wellness company focused on the scientific re-emergence of psychedelics and psychedelic-enhanced therapies.
It has treatment centres opening across North America, while it carries out drug development and advanced research on plant-based psychedelics through Field Trip Discovery.
And it has digital tools to support psychedelic experiences and consciousness expansion through Field Trip Digital.
“We help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world,” the company says.
Joining us at the Virtual One2One event will be founder and chairman Ronan Levy.
The keynote speaker for this psychedelics-focused event is one of the leading investors in this emerging and exciting space, Henri Sant-Cassia, founding partner of The Conscious Fund, the ethical VC for plant powered medicines.